NASDAQ:AXSMAxsome Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Axsome Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $55.02 -0.64 (-1.15 %) (As of 04/5/2020 04:00 PM ET) Add Compare Share Today's Range$54.37Now: $55.02▼$56.7850-Day Range$41.20MA: $73.88▼$92.5952-Week Range$13.25Now: $55.02▼$109.94Volume550,127 shsAverage Volume1.23 million shsMarket Capitalization$2.04 billionP/E RatioN/ADividend YieldN/ABeta3.11 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Axsome Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05, which is in the Phase III clinical trial for the treatment resistant depression; Phase II/III clinical trials in agitation associated with Alzheimer's disease; and Phase II clinical trial for the treatment of smoking cessation, as well as for major depressive disorder. The company is also developing AXS-07, which is in Phase III clinical trial for the treatment of migraine; AXS-12 that is in Phase II clinical trial for the treatment of in narcolepsy; AXS-09, which has completed Phase I clinical trial for the treatment of various CNS disorders; and AXS-02, which is in Phase III clinical trial for the treatment of the pain of knee osteoarthritis associated with bone marrow lesions, and for the treatment of chronic low back pain associated with Modic changes. In addition, it is developing AXS-06 that has completed Phase I clinical trial for the treatment of osteoarthritis and rheumatoid arthritis and for the reduction of the risk of nonsteroidal anti-inflammatory drug associated gastrointestinal ulcers. The company has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase II trial in smoking cessation. The company was founded in 2012 and is based in New York, New York.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingAxsome Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $108.11, Axsome Therapeutics has a potential upside of 96.5% from its current price of $55.02.Amount of Analyst CoverageAxsome Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesAxsome Therapeutics has received 323 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAxsome Therapeutics has received 283 “underperform” votes. (Add your “underperform” vote.)Community SentimentAxsome Therapeutics has received 53.30% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Axsome Therapeutics and other stocks. Vote “Outperform” if you believe AXSM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AXSM will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAxsome Therapeutics does not currently pay a dividend.Dividend GrowthAxsome Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Axsome Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 27.50% of the stock of Axsome Therapeutics is held by insiders.Percentage Held by Institutions60.07% of the stock of Axsome Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Axsome Therapeutics are expected to grow by 6.28% in the coming year, from ($2.39) to ($2.54) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Axsome Therapeutics is -27.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Axsome Therapeutics is -27.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAxsome Therapeutics has a P/B Ratio of 10.62. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.57 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AXSM Previous Symbol CUSIPN/A CIK1579428 Webhttp://axsome.com/ Phone212-332-3241Debt Debt-to-Equity Ratio0.10 Current Ratio9.00 Quick Ratio9.00Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.18 per share Price / Book10.62Profitability EPS (Most Recent Fiscal Year)($2.01) Net Income$-68,350,000.00 Net MarginsN/A Return on Equity-120.32% Return on Assets-75.17%Miscellaneous Employees29 Outstanding Shares37,080,000Market Cap$2.04 billion Next Earnings Date5/14/2020 (Estimated) OptionableOptionable Receive AXSM News and Ratings via Email Sign-up to receive the latest news and ratings for AXSM and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:AXSM Rates by TradingView Axsome Therapeutics (NASDAQ:AXSM) Frequently Asked Questions How has Axsome Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Axsome Therapeutics' stock was trading at $73.65 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, AXSM stock has decreased by 25.3% and is now trading at $55.02. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Axsome Therapeutics? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axsome Therapeutics in the last year. There are currently 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Axsome Therapeutics. When is Axsome Therapeutics' next earnings date? Axsome Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Axsome Therapeutics. How were Axsome Therapeutics' earnings last quarter? Axsome Therapeutics Inc (NASDAQ:AXSM) posted its earnings results on Thursday, March, 12th. The company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.48) by $0.23. View Axsome Therapeutics' earnings history. What price target have analysts set for AXSM? 9 brokers have issued twelve-month target prices for Axsome Therapeutics' shares. Their forecasts range from $25.00 to $200.00. On average, they anticipate Axsome Therapeutics' stock price to reach $108.11 in the next year. This suggests a possible upside of 96.5% from the stock's current price. View analysts' price targets for Axsome Therapeutics. Has Axsome Therapeutics been receiving favorable news coverage? Media coverage about AXSM stock has been trending very negative recently, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Axsome Therapeutics earned a media sentiment score of -3.3 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news aboutAxsome Therapeutics. Are investors shorting Axsome Therapeutics? Axsome Therapeutics saw a increase in short interest during the month of March. As of March 13th, there was short interest totaling 4,158,800 shares, an increase of 10.0% from the February 27th total of 3,780,000 shares. Based on an average trading volume of 761,400 shares, the days-to-cover ratio is presently 5.5 days. Currently, 20.1% of the company's shares are short sold. View Axsome Therapeutics' Current Options Chain. Who are some of Axsome Therapeutics' key competitors? Some companies that are related to Axsome Therapeutics include Sarepta Therapeutics (SRPT), Catalent (CTLT), Mylan (MYL), Ionis Pharmaceuticals (IONS), Dr.Reddy's Laboratories (RDY), ACADIA Pharmaceuticals (ACAD), Horizon Therapeutics (HZNP), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Ascendis Pharma A/S (ASND), Bausch Health Companies (BHC), Forty Seven (FTSV), Reata Pharmaceuticals (RETA), United Therapeutics (UTHR) and Evotec (EVTCY). What other stocks do shareholders of Axsome Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Axsome Therapeutics investors own include Inovio Pharmaceuticals (INO), Dicerna Pharmaceuticals (DRNA), NVIDIA (NVDA), Amarin (AMRN), Alibaba Group (BABA), Sarepta Therapeutics (SRPT), Viking Therapeutics (VKTX), AbbVie (ABBV), Micron Technology (MU) and Netflix (NFLX). Who are Axsome Therapeutics' key executives? Axsome Therapeutics' management team includes the following people: Dr. Herriot Tabuteau M.D., Founder, Chairman, CEO & Pres (Age 51)Mr. Nick Pizzie, CFO & Principal Accounting Officer (Age 44)Mr. Mark Jacobson, Sr. VP of Operations & Sec. (Age 36)Dr. Cedric O'Gorman M.D., MBA, Sr. VP of Clinical Devel. & Medical Affairs (Age 44)Joseph Debrah-Afful, Director of Fin. When did Axsome Therapeutics IPO? (AXSM) raised $52 million in an initial public offering on Thursday, November 19th 2015. The company issued 4,300,000 shares at $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. acted as the underwriters for the IPO and Brean Capital was co-manager. What is Axsome Therapeutics' stock symbol? Axsome Therapeutics trades on the NASDAQ under the ticker symbol "AXSM." How do I buy shares of Axsome Therapeutics? Shares of AXSM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Axsome Therapeutics' stock price today? One share of AXSM stock can currently be purchased for approximately $55.02. How big of a company is Axsome Therapeutics? Axsome Therapeutics has a market capitalization of $2.04 billion. The company earns $-68,350,000.00 in net income (profit) each year or ($2.01) on an earnings per share basis. Axsome Therapeutics employs 29 workers across the globe. View additional information about Axsome Therapeutics. What is Axsome Therapeutics' official website? The official website for Axsome Therapeutics is http://axsome.com/. How can I contact Axsome Therapeutics? Axsome Therapeutics' mailing address is 25 BROADWAY 9TH FLOOR, NEW YORK NY, 10004. The company can be reached via phone at 212-332-3241. This page was last updated on 4/5/2020 by MarketBeat.com StaffFeatured Article: Trading signals using Bollinger bands
